Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS in Yttrium-90 Radioembolization for HCC
NCT03300401Withdrawn
- Sponsor
- University of Southern California
- Start
- Nov 2017
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by University of Southern California. Primary endpoint: Local tumor response to therapy at 24 weeks. Planned start Nov 2017; status: withdrawn.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03300401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300401.